tbuckley/cabot-search huggingface dataset:
Effect of Coadministration of Phenobarbital Sodium on <italic>N</italic>-Nitrosodiethylamine-Induced γ-Glytamyltransferase-Positive Foci and Hepatocellular Carcinoma in Rats<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref>
Authors: M A Pereira, S L Herren-Freund, A L Britt, M M Khoury
Journal: JNCI Journal of the National Cancer Institute (1984)

The effect of concurrent administration of phenobarbital on the hepatocarcinogenicity of N-nitrosodiethylamine (diethylnitrosamine; DENA) in rats was investigated by determination of the incidence of γ-glutamyltransferase (γ-glutamyl-transpeptidase) (GGT)-positive foci and liver tumors. Male out-bred Sprague-Dawley rats received either a weekly oral dose of DENA (0.08 mol/kg), phenobarbital sodium (500 ppm) in their drinking water, or DENA and phenobarbital sodium concurrently. After 16 weeks, only the animals treated concurrently with DENA and phenobarbital sodium had GGT-positive foci (3.65 foci/cm2). At 30 weeks, the group treated with DENA and phenobarbital sodium exhibited more foci (23.6 foci/cm2) compared to the group that received only DENA (3.08 foci/cm2). The average size of foci in both of the DENA-treated groups was the same. The tumors in the group that received DENA plus phenobarbital sodium showed a greater incidence of GGT activity compared to the tumors in the DENA group. Under the conditions of this study the incidence of GGT-positive foci did not predict the incidence of hepatocellular carcinomas.
Problem-oriented postmortem examination.
Authors: A J Saladino, M L Dailey
Journal: BMJ (1978)

non-occupational infection has increased.Thus urban dwellers are increasingly at risk when they visit these areas as tourists, campers, and picnickers.Tick-borne encephalitis appears to be becoming increasingly prevalent, particularly in Austria, Czechoslovakia, and Yugoslavia.Although we have no recent figures, in 1963 there were 125 confirmed hospital cases in the Neunkirchen area of Austria; between 1960 and 1964 there were 365 hospital cases among holiday makers in Brno, Czechoslovakia; and in Yugoslavia almost 1500 suspected cases are reported annually, but only about 10' " are confirmed virologically (unpublished information from Dr Vesenjak-Hirjan).The reason for the increase in human infections is not clear but may be due to more awareness of the problem and better reporting.I ricinus populations do not appear to have increased and their wide- spread distribution in Europe has not altered despite reports to the contrary.3In Europe the disease shows a seasonal incidence cor- responding to two peaks in tick populations, May-June and September-October.I ricinus acts as both a vector and a reservoir, as it can pass the virus from one instar to another so that all developmental stages are infective.The virus can persist in the tick during the wintei and can also persist in hibernating animals such as rodents, shrews, and hedgehogs, which develop viraemia with the onset of warmer weather in spring.4Trying to control tick-borne encephalitis by destroying or reducing the number of wild vertebrate and arthropod hosts is difficult and expensive because of the large number of species concerned and the complexity of the virus-host ecosystems.Human vaccination would appear to be the only possible method of control.Recent vaccines prepared in chick embryo cell cultures using strains of tick-borne encephalitis derived from local isolates are producing encouraging results.
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
Authors: K Kobayashi, E E Vokes, N J Vogelzang, L Janisch, B Soliven, M J Ratain
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.9.2622 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8823342 Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose. K KobayashixK KobayashiSearch for articles by this author , E E VokesxE E VokesSearch for articles by this author , N J VogelzangxN J VogelzangSearch for articles by this author , L JanischxL JanischSearch for articles by this author , B SolivenxB SolivenSearch for articles by this author , M J RatainxM J RatainSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.9.2622 PDF "Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.." Journal of Clinical Oncology, 14(9), pp. 2622–2623© 1996 by American Society of Clinical Oncology
Quality of Life (Qol) Evaluation in Portuguese Lung Cancer Patients Receiving Chemotherapy-Associated Antiemetic Prophylaxis - Santarém Study
Authors: B. Parente, M.E. Teixeira, H. Queiroga, A. Fernandes, A. Araújo, M.T.A.S. Almodovar, J.C. Mellidez, F. Barata
Journal: Annals of Oncology (2014)
Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease
Authors: José J. Fuster, Noriyuki Ouchi, Noyan Gokce, Kenneth Walsh
Journal: Circulation Research (2016)

Obesity is causally linked with the development of cardiovascular disorders. Accumulating evidence indicates that cardiovascular disease is the collateral damage of obesity-driven adipose tissue dysfunction that promotes a chronic inflammatory state within the organism. Adipose tissues secrete bioactive substances, referred to as adipokines, which largely function as modulators of inflammation. The microenvironment of adipose tissue will affect the adipokine secretome, having actions on remote tissues. Obesity typically leads to the upregulation of proinflammatory adipokines and the downregulation of anti-inflammatory adipokines, thereby contributing to the pathogenesis of cardiovascular diseases. In this review, we focus on the microenvironment of adipose tissue and how it influences cardiovascular disorders, including atherosclerosis and ischemic heart diseases, through the systemic actions of adipokines.
The E Protein is a Multifunctional Membrane Protein of SARS-CoV
Authors: Qingfa Wu, Yilin Zhang, Hong Lü, Jing Wang, Ximiao He, Yong Liu, Chen Ye, Wei Lin, Jianfei Hu, Jia Ji, Jing Xu, Jia Ye, Yongwu Hu, Wenjun Chen, Songgang Li, Jun Wang, Jian Wang, Shengli Bi, Huanming Yang
Journal: Genomics Proteomics & Bioinformatics (2003)

Abstract The E (envelope) protein is the smallest structural protein in all coronaviruses and is the only viral structural protein in which no variation has been detected. We conducted genome sequencing and phylogenetic analyses of SARS-CoV. Based on genome sequencing, we predicted the E protein is a transmembrane (TM) protein characterized by a TM region with strong hydrophobicity and α-helix conformation. We identified a segment (NH2-_L-Cys-A-Y-Cys-Cys-N_-COOH) in the carboxyl-terminal region of the E protein that appears to form three disulfide bonds with another segment of corresponding cysteines in the carboxyl-terminus of the S (spike) protein. These bonds point to a possible structural association between the E and S proteins. Our phylogenetic analyses of the E protein sequences in all published coronaviruses place SARS-CoV in an independent group in Coronaviridae and suggest a non-human animal origin.
Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: Preliminary results from KEYNOTE-028.
Authors: Toshihiko Doi, Sarina Anne Piha-Paul, Shadia Ibrahim Jalal, Hieu Mai-Dang, Sammy Yuan, Minori Koshiji, Ildiko Csiki, Jaafar Bennouna
Journal: Journal of Clinical Oncology (2015)

4010 Background: Expression of the PD-1 ligands PD-L1 and PD-L2 has been associated with poor prognosis in esophageal cancer. Pembrolizumab is a highly selective humanized monoclonal antibody against PD-1 designed to block the interaction between PD-1 and PD-L1 and PD-L2. We assessed pembrolizumab safety and efficacy in pts with PD-L1+ esophageal carcinoma. Methods: KEYNOTE-028 (NCT02054806) is a nonrandomized, multicohort, phase Ib trial of pembrolizumab for PD-L1+ advanced solid tumors. Key eligibility criteria for this cohort included squamous cell carcinoma (SCC) or adenocarcinoma of the esophagus or gastroesophageal junction, measurable disease, PD-L1 expression in ≥ 1% of cells in tumor nests or PD-L1+ stromal bands determined centrally by IHC, failure of standard therapy, ECOG PS 0-1, and no autoimmune disease. Pembrolizumab 10 mg/kg is being given every 2 weeks for up to 2 years or until confirmed progression, unacceptable toxicity, or investigator decision. Response is assessed every 8 weeks for the first 6 months and every 12 weeks thereafter. Primary end points are safety, tolerability, and ORR per RECIST v1.1 by investigator review. Results: Of the 90 pts with esophageal cancer who were screened, 37 (41%) had PD-L1+ tumors. Of the 23 pts treated between March and December 2014, 83% were men and median age was 65. Histology was squamous in 77% of pts, adenocarcinoma in 18%, and mucoepidermoid in 5%. Eighty-seven percent of pts received ≥ 2 prior therapies for metastatic disease; all pts received ≥ 1 platinum-based therapy. Six pts (26%) experienced drug-related adverse events (DRAEs), including 2 (9%) who experienced grade 3 DRAEs. There were no grade 4 DRAEs, and no pts died or discontinued due to a DRAE. ORR (confirmed and unconfirmed) was 23% (n = 5); best response was stable disease in 18% (n = 4) and progressive disease in 59% (n = 13). One pt did not have response assessed at the time of analysis. Six pts, including all responders, remain on treatment. Conclusions: Pembrolizumab has an acceptable safety profile and provides promising antitumor activity in pts with heavily pretreated, PD-L1+ advanced esophageal carcinoma. These data support further study of pembrolizumab for pts with esophageal carcinoma. Clinical trial information: NCT02054806.
Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients
Authors: N Price, W Glazer, H Morgenstern
Journal: American Journal of Psychiatry (1985)

The authors examined the records of 397 outpatients maintained on antipsychotic medication to identify demographic characteristics that predicted use of depot medication. Patients maintained on long-acting antipsychotics tended to be young, male, and black. The age effect was largely restricted to white patients.
CLINICAL NOTES
Authors: JACKSON A. SMITH
Journal: American Journal of Psychiatry (1953)

Thirty-three patients who were anxious, depressed, or hysterical were treated by inhalation with a mixture of 30% carbon dioxide and 70% oxygen. These patients were followed from 6 months to 2 years. Of this group, 4 patients responded promptly and sustained their improvement. Eight patients showed slight and usually temporary improvement over a period of 6 to 8 weeks. Improvement is defined as a decrease in the number and severity of the symptoms and a return to a premorbid level of adjustment. Twenty-one of the 33 patients received no appreciable help from this method of treatment and in this series this procedure was considered to be of limited value.
Abstract P5-10-04: Care guidelines for young women diagnosed with breast cancer
Authors: MJ DeCoteau
Journal: Cancer Research (2016)

Abstract Background: Rethink Breast Cancer has been offering educational resources and front-line psychosocial and practical support to younger women with breast cancer for over ten years. We have heard first-hand the unique issues that these women face. Some of these challenges include diagnosis during pregnancy, effects of chemotherapy on fertility, risk of menopausal symptoms or osteoporosis, feelings of isolation, questions about sexuality, childcare, relationships, dating, employment and money. Purpose: Health Canada and the Canadian Medical Association have established comprehensive Clinical practice guidelines for the care and treatment of breast cancer and our Provincial Cancer Agencies, the Canadian Association of Nurses in Oncology (CANO) and the Canadian Association of Psychosocial Oncology (CAPO) all have developed excellent Standards of Care. However, our report, Breast Cancer in Young Women in Canada – A Needs Assessment, finds that younger women's needs continue to fall through the cracks. The report also shows that despite a growing array of peer support based interventions and community resources for young women with breast cancer, their needs are often not being met by current healthcare systems. In response to the feedback from young women experiencing breast cancer in Canada provided in our report, Rethink Breast Cancer has developed a set of recommended Care Guidelines for Young Women with Breast Cancer to ensure their special needs are addressed (in a timely matter). They serve as a compliment to the guidelines mentioned above. Methods: The care guidelines have been developed in consultation with Rethink's Young Women's Network, a group comprised of young women across the Canada that have personal experience with breast cancer and are interested in Rethink's unique role within the breast cancer community. The network provides important input and feedback on our resources and campaigns for young women dealing with breast cancer. The care guidelines were also developed through consultation with our professional advisors in oncology, nursing and psychosocial support. They are based on original work by UK specialist breast cancer support charity Breast Cancer Care. Results &amp; Conclusions: These guidelines provide information about key issues individuals may want to discuss with their healthcare providers involved in their breast cancer treatment and care. They are recommendations on the kind of information and support to which individuals should be given access to as a younger woman with breast cancer. They will also serve to guide the care these individuals receive from healthcare professionals. Citation Format: DeCoteau MJ. Care guidelines for young women diagnosed with breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-10-04.
EPA Awards Climate Change Air Quality Grants
Authors: Julie A. Jacob
Journal: JAMA (2016)

The Environmental Protection Agency (EPA) has awarded $8.5 million to 12 universities across the country that are conducting research on how to protect air quality from climate change–associated effects (http://1.usa.gov/1STSDCm).

“The research funded by these grants will improve our understanding of how climate change is impacting our air and our health,” said Thomas A. Burke, PhD, the EPA’s office of research and development’s deputy assistant administrator in a statement. “By examining the relationship between air quality and climate change, this research will help better protect human health and the environment.”
Infectivity Tests of Secretions and Excretions From Cattle Infected With Bovine Leukemia Virus&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: J M Miller, M J Van der Maaten
Journal: JNCI Journal of the National Cancer Institute (1979)

Secretions and excretions from cattle with persistent bovine leukemia virus (BLV) infections were tested for BLV by inoculation into sheep. Development of antibody to the BLV glycoprotein antigen and reisolation of virus from peripheral blood leukocytes were the two criteria used to confirm infection in test sheep. The virus was detected in milk from 4 of 6 cows examined and in colostrum from 1 of 4 cows examined. The virus was not detected in semen from 8 bulls or in nasal secretions, saliva, and urine from 2 cows.
Evans Blue as a Diagnostic Test for Amyloidosis
Authors: E S CATHCART, A S COHEN
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mammary Cancer in Mice Observed in Different Laboratories and During the War Period&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: John J. Bittner
Journal: JNCI Journal of the National Cancer Institute (1954)

Mammary Cancer in Mice Observed in Different Laboratories and During the War Period Get access John J. Bittner John J. Bittner Division of Cancer Biology, Department of Physiology, University of Minnesota Medical School, Minneapolis, Minn. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 2, October 1954, Pages 359–366, https://doi.org/10.1093/jnci/15.2.359 Published: 01 October 1954 Article history Received: 30 June 1954 Published: 01 October 1954
Electronic real-time surveillance for influenza-like illness: experience from the 2009 influenza A(H1N1) pandemic in Denmark
Authors: K M Harder, P H Andersen, I Bæhr, L P Nielsen, S Ethelberg, S Glismann, K Mølbak
Journal: Eurosurveillance (2011)

To enhance surveillance for influenza-like illness (ILI)in Denmark, a year-round electronic reporting system was established in collaboration with the Danish medical on-call service (DMOS). In order to achieve real-time surveillance of ILI, a checkbox for ILI was inserted in the electronic health record and a system for daily transfer of data to the national surveillance centre was implemented. The weekly number of all consultations in DMOS was around 60,000, and activity of ILI peaked in week 46 of 2009 when 9.5% of 73,723 consultations were classified as ILI. The incidence of ILI reached a maximum on 16 November 2009 for individuals between five and 24 years of age, followed by peaks in children under five years, adults aged between 25 and 64 years and on 27 November in senior citizens(65 years old or older). In addition to the established influenza surveillance system, this novel system was useful because it was timelier than the sentinel surveillance system and allowed for a detailed situational analysis including subgroup analysis on a daily basis.
Observations on Tryptophan Staining of the Pancreatic &lt;italic&gt;Alpha&lt;/italic&gt; Cells
Authors: Herbert J. Levine, George G. Glenner
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Observations on Tryptophan Staining of the Pancreatic Alpha Cells Get access Herbert J. Levine, Herbert J. Levine National Cancer Institute,4 and National Institute of Arthritis and Metabolic Diseases,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar George G. Glenner George G. Glenner National Cancer Institute,4 and National Institute of Arthritis and Metabolic Diseases,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 1, January 1958, Pages 63–69, https://doi.org/10.1093/jnci/20.1.63 Published: 01 January 1958 Article history Received: 28 June 1957 Published: 01 January 1958
Waldenstrom's Macroglobulinaemia
Authors: V Jayapal, M Thomas, S Mathew, J Augustine, K Santhamma, N Vijayalekshmi, G V Rajan, K P Chandrasekhar
Journal: BMJ (1965)

Waldenstrom's macroglobulinaemia is a rare form of monoclonal plasma cell dyscrasia in which there is excess production of immunoglobulin M. Clinically the patient has features of hyperviscosity syndrome and the effects of bone marrow replacement by lympho-plasmacytoid cells. We report here two such cases seen within a period of two months.
Dietary Salt, Kidney Disease, and Cardiovascular Health
Authors: Neil R. Powe, Kirsten Bibbins-Domingo
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intracellular Action of a Secreted Peptide Required for Fungal Virulence
Authors: Christina M. Homer, Diana K. Summers, Alexi I. Goranov, Starlynn C. Clarke, Darin L. Wiesner, Jolene K. Diedrich, James J. Moresco, Dena Toffaletti, Rajendra Upadhya, Ippolito Caradonna, Sarah Petnic, Veronica Pessino, Christina A. Cuomo, Jennifer K. Lodge, John Perfect, John R. Yates, Kirsten Nielsen, Charles S. Craik, Hiten D. Madhani
Journal: Cell Host & Microbe (2016)
Growth Factors, Act II: Movement Into and Through Clinical Trials
Authors: J Ziegler
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Growth Factors, Act II: Movement Into and Through Clinical Trials Get access JNCI: Journal of the National Cancer Institute, Volume 81, Issue 12, 21 June 1989, Page 888, https://doi.org/10.1093/jnci/81.12.888 Published: 21 June 1989
Barrie Vernon-Roberts
Authors: Mark Vernon-Roberts
Journal: BMJ (2016)

Barrie Vernon-Roberts, an outstanding researcher into bone and joint pathology, spinal disease, and inflammation has died in Adelaide aged 80.

The second of four brothers, he was born and brought up in rural north Wales. He was educated at Ruthin School, where he won many academic prizes as well as excelling as a rugby player and middle distance runner. An outstanding medical student, he won prizes including the Llewellyn scholarship as the outstanding graduate of the year. He was captain of the athletics and golf teams as well as representing the hospital at rugby.

After house jobs at Charing Cross he took the post of anatomy lecturer at King’s College with a view to a career in surgery. However, under Professor Nicol he quickly became involved in research into the influence of hormones on the reticuloendothelial system, publishing his first paper in 1963. The work led to a PhD degree in 1965 and MD in 1966. In 1972 he was invited to write a monograph, The Macrophage , that was published by Cambridge University Press in 1972.

In 1969 he was appointed senior lecturer in the Department of Morbid Anatomy at the Royal London Hospital …